Cytokine release syndrome preventative therapy could be a >$10bn market opportunity

Positive outputs from lab-based analysis of RSV drug candidates identified using AI

Poolbeg Pharma PLC announces directorate change

Poolbeg Pharma to use unique oral delivery platform for new condition

Poolbeg Pharma completes clinical trials for viral strain agnostic

Poolbeg-led consortium awarded €2.3m in funding